Invizius Pennsylvania Massachusetts Scotland

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

at the Pennsylvania Convention Center in Philadelphia, PA, on 2 to 5 November. Do get in contact if you would like to set up a meeting or require further information.

About Invizius

Invizius is developing a portfolio of second generation complement therapies to address a range of autoimmune and inflammatory diseases. Invizius' proprietary approach was born out of over ten years of research by Dr Andy Herbert into how pathogenic microbes evade the human complement system. The novel mechanism of action enhances the activity of the body's own complement regulators to effectively downregulate immune responses while maintaining antimicrobial protection. The lead product, H-Guard, addresses serious complement-driven complications of haemodialysis, and enables additional indications in other extra-corporeal treatments (ECMO, cardiopulmonary bypass). A second product is being developed to extend the period that patients can sustain home-based, peritoneal dialysis.

The company is working with Key Opinion Leaders from University of Manchester NHS Trust, Karolinska Institutet, University of Heidelberg, University Medical Centre Groningen, University of Oxford, and University of Strathclyde. It is backed by Mercia, Downing, Calculus, and Solvay, a corporate VC. Other investors include Edinburgh University's Old College Capital fund, Scottish Enterprise, and well-known life science investor, Dr Jonathan Milner.

For more information on Invizius, please visit: www.invizius.com

View original content:https://www.prnewswire.co.uk/news-releases/invizius-announces-appointment-of-world-renowned-nephrologist-professor-bernard-canaud-to-its-clinical-advisory-board-301965000.html